Fresnillo (LSE: FRES): Can the world’s largest silver miner hold its record gains as 2026 output dips?
TCS CEO corrects three major Nashik facts: Nida Khan was not HR head, unit not shut, no POSH complaints on record
Read More Pharma Industry News EMA clears Curasight’s uTREAT trial—will targeted radiopharma redefine brain cancer therapy? Curasight wins EMA approval for its first uTREAT clinical trial in glioblastoma. Find out how its theranostic strategy could change brain cancer treatment. byPallavi MadhirajuAugust 26, 2025